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Abstract: Astaxanthin is a carotenoid extracted from several seaweeds with ascertained therapeutic
activity. With specific reference, astaxanthin is widely used in clinical practice to improve ocular
tissue health and skin protection from UV ray damages. Despite its well-documented pleiotropic
actions and demonstrated clinical efficacy, its bioavailability in humans is low and limited because of
its hydrophobicity and poor dissolution in enteric fluids. Furthermore, astaxanthin is very unstable
molecule and very sensitive to light exposure and thermal stress. Taken together, these pharmacological
and chemical–physical features strongly limit pharmaceutical and nutraceutical development of
astaxanthin-based products and as a consequence its full clinical usage. This work describes the
preliminary in vitro investigation of sublingual absorption of astaxanthin through a novel ascorbyl
palmitate (ASP) based nanoemulsion.




4,4-trimethyl-1-cyclohex-2-enone) (Figure 1) is a lipid-soluble xanthophyll keto-carotenoid with
molecular mass 596.841 g/mol [1].
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 (C40H52O4; S)-6-Hydroxy-3 [(1E,3E,5E,7E,9 , 1 , 3 ,15E,17E)-18-[(4S)-4-
hydroxy-2,6,6-trimethyl-3-oxo-1-cyclohexenyl] 3,7,12,16-tetramethyloctadeca- ,3,5,7,9,11,13,15,17-
nonaenyl]-2,4,4 trimethyl-1-cyclohex-2-enone) (Figure 1) is a lipid-soluble xanth phyll keto-
carotenoid with molecular mass 596.841 g/mol [1]. 
 
Figure 1. Structure of Astaxanthin. 
It is the responsible of the red color of some crustaceous and fishes [2]. The most known 
pharmacological activity of astaxanthin is the antioxidant one [3] but, contrary to other carotenoids, 
[4] it seems to also exert direct anti-inflammatory activity and to activate Peroxisome Proliferator-
Activated Receptors [5]. 
In (usually small and short-term) clinical trials, oral supplementation with astaxanthin not 
associated with other nutraceuticals has demonstrated to be protective against UV-induced skin 
deterioration and helps maintain healthy skin in healthy people [6], to improve liver parameters in 
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climacteric women [7], to protect the vocal fold from injury and inflammation caused by vocal loading [8],
to increase the choroidal blood flow velocity in healthy subjects [9], to reduce LDL-cholesterolemia and
oxidative stress in overweight patients [10,11], to increase HDL-cholesterolemia and serum adiponectin
levels in mildly dyslipidaemic subjects, [12] to prevent oxidative damage in smokers by suppressing
lipid peroxidation and stimulating the activity of the antioxidant system [13], and to improve symptoms
in patients affected by functional dyspepsia (especially if infected by Helicobacter pylori) [14].
In some trials, supplementation with astaxanthin was also shown to prevent and reduce oxidative
stress in young soccer players, [15,16] but not in well-trained cyclists [17]. In a previous study,
it improved performance in cyclists, [18] while in a recent study it does not augment fat use or improve
endurance performance [19]. However, a recent randomized controlled clinical trial showed no effect
of astaxanthin on arterial stiffness, oxidative stress, or inflammation in renal transplant recipients [20].
The apparent contrast between positive and neutral effects observed in clinical trials are mainly
related to the different dosage used, but also to the largely different bioaccessibility of the tested
pharmaceutical forms [21].
It is well ascertained, indeed, that astaxanthin is poorly bioavailable in humans [22] from the
conventional pharmaceutical forms, particularly because of its high lipophilicity that precludes the
overall enteric bioaccessibility and because it can be enhanced by modified lipids and surfactants
capable of making it more hydro-dispersible [23].
Many attempts have been dedicated to projecting pharmaceutical forms with the aim of improving
bioaccessibility and overall bioavailability of astaxanthin and in this frame, nanoemulsions seem to
play a pivotal role according to numerous published papers [24–26].
Given the potential interest of developing more effective forms of astaxanthin supplements,
the aim of our study was to evaluate, likely for the first time, a novel liquid nanoemulsion to promote
astaxanthin sublingual delivery by means of an in vitro model assessing its permeation through porcine
lingual specimens.
2. Materials and Methods
2.1. Materials
A Franz cells device was purchased from Copley Scientific (Nottingham, UK), surgical blades from
Tekno Optik-Chirurgie GmbH (Tuttlingen, Germany), and scalpel handle from Moretti Spa (Cavriglia,
Arezzo, Italy). Malvern Zetasizer Nano series (DLS device) was purchased from Malvern Panalytical
(Mlavern, UK). A HPLC-DAD device was purchased from Perkin-Elmer (Series 200, diode array,
Waltham, MA, USA). A mechanical stirrer (LG series) and heating plate (RC series) were purchased
from Velp Scientifica (Usmate, MB, Italy). Astaxanthin (AstapureTM 10% titration in astaxanthin)
was purchased from AlgaTech (New York, NY, USA), astaxanthin standard analytic (>97% from
Hematococcus pluvialis) was purchased from Sigma-Aldrich (Milan, Italy), physiological solutions were
purchased from BS Medital Spa (Grosotto, SO, Italy). Polysorbate 80 (Veremul T 80) was purchased
from Veronelli SPA, Milan, Italy; ascorbyl palmitate was purchased from ACEF, Fiorenzuola, Piacenza,
Italy; caprylic/capric triglycerides (Labrafac Lipophile WL 1349) were purchased from Gattefossè,
Milan, Italy; deionized water was obtained from inverse osmosis industrial device.
2.2. Preparation of Porcine Sublingual Epithelium
For the experiments, fresh pork tongue was used. Pig’s tongue was obtained from a 6-month-old
pig, weighing around 80 kg. The tongue was withdrawn in a local slaughterhouse, transported to the
laboratory under vacuum, and immediately used (within 2 h).
Initially, the tongue was placed in physiological solution for about ten minutes, then washed
out with new physiologic solution three times, and then sectioned to get the epithelium specimens.
The sublingual (ventral) epithelium was sectioned using a scalpel to separate it from underlying
connective tissue (Figure 2).
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Before clamping the epithelium into the Franz cell chamber (Figure 3), it was washed with PBS
10× pH 6.6–7.4 three times [27,28].
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Deionized water Up to 100 g
AstapureTM 0.15% w/2 Astaxanthin
Emulsion was prepared incorporating AstapureTM (10% w/w in astaxanthin) in the oily phase (equal
to 0.15% w/w theoretic value of astaxanthin on the total nanoemulsion) composed of caprylic/capric
triglyceride, and polysorbate 80 (PS 80) and ascorbyl palmitate, as the main high hydrophilic–lipophilic
balance emulsifying agent and co-emulsifying agent, respectively. The preparation of the oily phase
and the further steps to achieve the nanoemulsion were carried out in a dark room to protect astaxanthin
from UV rays. Both the oily and water phases were warmed up at 50 ◦C and the final emulsification
process was carried out at this temperature, slowly pouring the water phase into the oily phase
under high-speed mechanical stirring. Soon after, the system was cooled down by placing the beaker
containing nanoemulsion, appearing as a perfectly clear system with an intense red color (Figure 4),
in an ice-water bath, maintaining low-speed stirring until the room temperature was reached, according
to low energy PIT method [29–31].
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2.5. Permeation Experiments
The incisions were made starting from the ventral part of the swine tongue, with particular
attention given to removing only the outermost layer which, once cut, is completely transparent.
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Once the external epithelial tissue was sectioned, it was gently positioned in the appropriate space
between the donor and the receiving chamber. A total amount of 1.26 g of the astaxanthin-containing
nanoemulsion (equal to total 0.189 g of astaxanthin) was inserted from the upper apex, in the donor
compartment of the Franz cell and placed at 37 ◦C under magnetic agitation (210 rpm). The acceptor
chamber was filled up with degassed solution of PBS 10× (10 mL). The cells, before the start of the
experiments, were allowed to equilibrate for 60 min in a water bath at 37 ◦C (according to Franz-Montan
2016) [26].
A stirrer was necessary to keep the system in a continuous flow to carry out solution withdrawals
in which the active permeation is homogeneously dispersed. The samples were withdrawn after
15’, 30’, 60’, 2 h, 4 h. Samples (1 mL) were withdrawn from the receiving chamber for the HPLC
analysis and the volume was replaced with the same amount of fresh buffer PBS, taking account of
dilution effects.
The data obtained from the HPLC analysis relating to the title of astaxanthin in the receptor chamber
were converted into mass per unit of surface (µg/cm2) of the permeating membrane. The surface area
of the porcine lingual epithelium inserted in the chamber was calculated, starting from the chamber
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where dCa/dt is the slope (s) of the linear correlation between the change in concentration of permeated
astaxanthin in the infinitesimal time change, A is the permeation surface, Cd is the concentration on
the donor compartment, and Va is the volume of the acceptor chamber [32]. Once the permeability
coefficient (Pe) was calculated, according to Bortolotti F. et al. (2009), the flux at the steady state (Jss)
was also calculated through the following Equation (3):
Jss = Pe ×Cd (3)
where Jss is the flux at the steady state, Pe is the permeability coefficient, and Cd is the concentration of
astaxanthin in the donor chamber [33].
Experiments were realized in triplicate (n = 3) and mean value of astaxanthin concentration (±SEM)
permeated in the receptor liquid, at any time of withdrawal, was used to calculate the concentration
of astaxanthin per cm2 (±SEM), flux (Jss) (±SEM), and apparent permeability coefficient (Pe) (±SEM).
Statistical elaboration of the data collected was realized through software SPSS according to T-Student
method (p < 0.05).
2.6. Titration of Astaxanthin in Raw Material, Nanoemulsion, and Permeation Specimens
Firstly, 100 mg of AstapureTM (10% astaxanthin containing oil, raw material employed to fabricate
nanoemulsion) was solubilized in 100 mL of acetone. Then, 500 mg of nanoemulsion containing
astaxanthin was weighted in analytical balance and then solubilized in 100 mL of acetone. After that,
the samples were sonicated for 15 min and then centrifuged and placed in vials. The samples were
analyzed through High-Performance Liquid Chromatography with Diode-Array Detection coupled
with UV-analyzer (HPLC-DAD-UV), DAD scan range was from 200 to 800 nm, with stationary phase
composed of YMC Carotenoid column 4.6 mm I.D.× 250 mm (C30 bonded silica, Particle size: 5 µm,
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usable pH range: 2.0–7.5): YMC Carotenoid stationary phase provides sufficient phase thickness
to enhance interaction with long chained molecules, therefore, geometric and positional isomers
of conjugated double bonding systems, typical of carotenoids and their esters, are recognized and
resolved [34]. Mobile phase composed of methylterbutil ether (MTBE)/methanol 90:10 and methanol.
The flux was set at 1.3 mL/min and the wave length set at 470 nm. The same method was applied to
assess titration of astaxanthin from the permeation specimens. Thanks to this procedure, encapsulation
efficiency Ee of the fresh fabricated nanoemulsion was calculated according to Equation (4) [35]:
Ee (%) = CAst × 100 (4)
where Ee is the encapsulation efficiency and CAst is the concentration of astaxanthin loaded in the
nanoemulsion during fabrication (time 0).
The titration results were expressed as the mean and standard error of the mean (±SEM) for each
variable studied.
3. Results and Discussion
3.1. Dimensional Characterization of Astaxanthin Containing Nanoemulsion
Figures 5–7 clearly show that astaxanthin containing nanoemulsion is characterized by a single,
narrow, well-shaped pick, both for the measures by number and volume weighting. The average
diameter of the oily droplets is around 20 nm (z-average d.nm). The PDI of 0.2 indicates a low
poly-dispersion profile with a quite uniform dispersion of the droplets. Under physical point of view,
considering the average dimension of the particles and according to the published papers (refer to the
section Supplementary File), this system can be considered “border-line” between a nanoemulsion and
a microemulsion. Nanoemulsion, indeed, is defined as a clear kinetically stable and thermodynamically
unstable liquid system, with average particles size ranging from 100 to 200 nm and a microemulsion is
defined as a clear, bicontinous, kinetically and thermodynamically stable liquid system with average
particle sizes lower than 50 nm. Thanks to these evidences, it is possible to argue that this system can be
particularly capable of enhancing superficial surface of contact between the active ingredient entrapped
in the dispersed oily phase and epithelium, in this case, lingual epithelium. Since astaxanthin is a
lipophilic molecule easily soluble in oils and insoluble in water, nano-encapsulation can be hugely
advantageous for efficient delivery through the lingual epithelium.
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3.2. Titration of Astaxanthin in Raw Material and Nanoemulsion
Figure 8 confirms the presence of astaxanthin in both AstapureTM raw material and nanoemulsion
with the characteristic pick at 6, 7 min. The analysis of the graph also shows a group of picks (8,
5–12 min) indicating products derived from or analogues f staxanthin characterized by the same UV
spectru with peculiar absor tion pick at 470 nm. According to Ranga et al. (2009), the mentioned
picks (8–12 min) recognized in the chromatogram obtained with HPLC-DAD are mainly ascribable to
astaxanthin mono and diesters [36], present in Asta ureTM, an extract derived from Haematococcus
pluvialis hat is indeed char cter zed by t e high content of astaxanthin in the form of fatty acid esters
with he predominan presence f monoest r, about 70% w/w [36], that very likely corresponds to the
highest ick at about 9 min in hromat gram 1. As fu ther confirmation, the analytical facts data
sheet of AstapureTM reports the presence of natural astaxanthin complex in addition to other free
carotenoids suc as lutein and zeaxanthin. From the titration, it was confirmed that nanoemulsion
contains 0.15% w/w of astaxanthin, according to the 1.5% w/w amount of AstapureTM titrated at 10%
w/w of astaxanthin complex, loaded during the preparation of the nanoemulsion (Table 2).
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nanoemulsion. Results are expressed as mean ± SEM.
Sample /w as Total Astaxant i
AstapureTM 10.04 ± 0.09
Nanoemulsion 0.151 ± 0.006
This data, apart from the confirmation of the correct content of astaxanthin in the nanoemulsion,
gives account of the stability of astaxanthin during nanoemulsion preparation: Astaxanthin is
notoriously a very unstable molecule [37] and can be promptly and massively degraded when
subjected to heat and UV exposure. The measures of dark room and low thermal energy chosen during
the phases of preparation of the nanoemulsion allowed the full recovery of astaxanthin into the final
system as the excellent data of encapsulation efficiency Ee confirms (Table 3).
Table 3. Ee of Astaxanthin in the nanoemulsion.
AstapureTM loaded 1.5 g/
CAst in nanoemulsion 0.15 gt/100 mL
Nanoemulsion Ee (%) 100
Moreover, it can be argued that astaxanthin can be stabilized throughout the nanoemulsion
preparation process and over time by ascorbyl palmitate (ASP), that is notoriously a lipidic antioxidant
that can protect isopre oid structur of astaxanthin and prevent it from being oxidized.
3.3. Titration of Astaxanthin in Permeation Specimens
According to Figures 9 and 10 in which the permeation rate of astaxanthin and its derivatives
is represented through the HPLC-DAD titration on the five permeates specimens, as reported in
Sections 2.6 a 3.2, it is possible to recognize the peculiar astaxanthin pick in every sampl . Incr asing
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concentration of astaxanthin and its derivatives was registered in specimens over time (Table 4),
indicating that astaxanthin and its derivatives accumulated in the permeated receptor liquid reaching
the plateau at 2 h. From 1 h specimen to 2 h specimen, the concentration of astaxanthin and its
derivatives shows a 21-fold increase (Table 4). Flux (Jss) and Apparent Permeability (Pe) of astaxanthin
from the nanoemulsion are equal to 6.27 ± 0.022 µm/cm2/h and 41.55 ± 0.442 cm/h respectively;
the total amount of astaxanthin permeated after 4 h is equal to 23.6% (25.1 ± 0.24 mcg/cm2) of the total
amount loaded in the donor compartment entrapped in the nanoemulsion (189 mcg). The amount of
astaxanthin retained in the lingual tissue was not determined.
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Table 4. Concentration of astaxanthin (nanoemulsion) permeated expressed as µg/mL and µg/cm2.
Results are expressed as mean ± SEM.
Specimen µg/mL Astaxanthin and Derivates µg/cm2 Astaxanthin and Derivates
Permeated 15 min 0.019 ± 0.001 0.0108 ± 0.001
Permeated 30 min 0.025 ± 0.004 0.0142 ± 0.001
Permeated 1 h 0.102 ± 0.023 0.0577 ± 0.008
Permeated 2 h 2.116 ± 0.002 1.1980 ± 0.012
Permeated 4 h 2.184 ± 0.073 1.2365 ± 0.009
Comparing this data with that collected from Odeberg et al. [23] (Wagner–Nelson method),
assessing astaxanthin bioavailability in humans from different formulations assumed orally containing
40 mg of the carotenoid with or without absorption enhancers (PS 80, Glycerol mono and dioleate,
SPAN 80), it is possible to recognize comparable data of percentage of absorption over time (4 h)
ranging from 4% (formulation without absorption enhancers) to 34% (PS 80 + SPAN 80). Despite this,
the data are far from being completely comparable given the differences in experimental design and
approach, model and the route of administration, the high hydrophilic–lipophilic balance surfactants
such as PS 80, and the technological approaches capable of enhancing astaxanthin hydro-dispersibility
that improve astaxanthin bioavailability seem to be confirmed.
4. Conclusions
Astaxanthin is a carotenoid that attracts the attention of clinicians for its well ascertained potential
therapeutic activity, especially in the fields of ocular and skin health and cardiovascular disease
prevention. Despite this clinical potential, astaxanthin bioavailability and stability are low and limited.
Since astaxanthin is a very lipophilic molecule, the only way to deliver it in a water-based liquid system
is to create an emulsion. According to this concept, liquid nanoemulsion seems to be a promising
technical system for releasing astaxanthin through the lingual epithelium.
The data collected in this work show for the first time that astaxanthin can be delivered in
a nanoemulsion through the lingual district, opening an interesting path to improving its poor
bioavailability when assumed by the oral route. In particular, the nanoemulsion herewith described,
is characterized by a good uniformity of dispersion, very low dimension of the oily droplets (around
20 nm), close to those of a microemulsion, and overall can be considered an effective and innovative
pharmaceutical form for entrapping astaxanthin as the encapsulation efficiency data confirms. It is
also important to emphasize that the peculiar association of surfacing agents employed to achieve
this system, with specific reference to ASP, provides an overall good stability of astaxanthin during
the process of nanoemulsion fabrication. This fact is of particular significance in consideration
of the notorious instability of the molecule that prevents its full clinical usage. From the data
collected regarding astaxanthin permeation behavior, it is possible to argue that astaxanthin reaches
a pseudo-linear permeation trend during the second hour and then reaches a plateau, confirming
that a quasi-steady state diffusion can be described. Taken together, these data confirm that a
novel pharmaceutical form projected to deliver astaxanthin through the sublingual route has been
achieved and characterized, and thanks to this peculiar form, this route can be considered, even though
preliminarily, a potential effective alternative to enhance the bioavailability of this carotenoid, potentially
improving its therapeutic potential. A confirmation of these preliminary data should be achieved with
a pharmacological assessment of the kinetic profile of astaxanthin-containing nanoemulsion through
the sublingual route in healthy human volunteers.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-3397/17/9/508/s1,
Text S1 Thermodynamic topics of nanoemulsions and microemulsions; Text S2. Synergy between Ascorbyl
Palmitate and Polysorbate in the production of nanoemulsion.
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